AQST · ISSUER CIK 1398733
Aquestive Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Aquestive Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $379K of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$379KInsider selling
−$379KNet open-market
Oct 23, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 202613:38 | Oct 21, 2026 | AQST | Director | J · Other | — | +62,229 | 161,715 | +63% | — | ||
| Oct 16, 202614:17 | Oct 15, 2026 | AQST | President and CEO, Director | S · Sell10b5-1 | $4.22 | −25,000 | 627,317 | -4% | −$106K | ||
| Sep 16, 202614:00 | Sep 15, 2026 | AQST | President and CEO, Director | S · Sell10b5-1 | $4.82 | −25,000 | 652,317 | -4% | −$120K | ||
| Sep 11, 202611:07 | Sep 9, 2026 | AQST | Chief Commercial Officer | S · Sell10b5-1 | $5.22 | −8,750 | 235,689 | -4% | −$46K | ||
| Sep 11, 202611:07 | Sep 9, 2026 | AQST | Chief Commercial Officer | M · Exercise10b5-1 | $2.65 | +8,750 | 244,439 | +4% | $23K | ||
| Sep 10, 202609:21 | Sep 9, 2026 | AQST | Chief People Officer | X · Exercise | $0.96 | +2,293 | 284,024 | +1% | $2K | ||
| Sep 9, 202617:10 | Sep 8, 2026 | AQST | President and CEO, Director | X · Exercise | $0.96 | +91,743 | 677,317 | +16% | $88K | ||
| Sep 8, 202616:06 | Sep 3, 2026 | AQST | Chief Operating Officer | X · ExerciseLate 5d | $0.96 | +4,587 | 206,833 | +2% | $4K | ||
| Aug 18, 202616:13 | Aug 17, 2026 | AQST | President and CEO, Director | S · Sell10b5-1 | $4.29 | −25,000 | 585,574 | -4% | −$107K | ||
| Aug 17, 202617:33 | Aug 14, 2026 | AQST | Chief Commercial Officer | F · Tax | $4.25 | −2,714 | 235,689 | -1% | $12K |